Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.47 |
| ▸ | TBXAS1 | P24557 | 10/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.44 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9528603 | 0.89 | CYP19A1 (0.50) | TBXAS1TBXA2R | |
| SCHEMBL9528596 | 0.89 | CYP19A1 (0.50) | TBXAS1TBXA2R | |
| SCHEMBL8511316 | 0.87 | SIGMAR1 (0.53) | SIGMAR1TBXAS1TBXA2R | |
| SCHEMBL8216126 | 0.87 | SIGMAR1 (0.53) | SIGMAR1TBXAS1TBXA2R | |
| SCHEMBL9092744 | 0.85 | SIGMAR1 (0.53) | SIGMAR1TBXAS1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL7535000 | 0.81 | MTNR1A (0.47) | SIGMAR1TBXAS1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL9525610 | 0.80 | SIGMAR1 (0.44) | SIGMAR1PTPN1 | |
| SCHEMBL9525605 | 0.80 | SIGMAR1 (0.44) | SIGMAR1PTPN1 | |
| SCHEMBL9717829 | 0.79 | TBXAS1 (0.53) | SIGMAR1TBXAS1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL10991192 | 0.78 | TBXAS1 (0.40) | TBXAS1MTNR1AMTNR1BPTPN1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7488755-B2 | Derivatives of glycinergic R(+)-2-amino-3-hydroxypropanoic acid | PRESTWICK PHARMACEUTICALS, INC. (US) | 2009-02-10 | — | — | US | disclosed |
| US-20060287298-A1 | Pharmaceutical for treatment of neurological and neuropsychiatric disorders | ALLELIX NEUROSCIENCE INC. | 2006-12-21 | — | — | US | disclosed |
| EP-1014966-B1 | PHARMACEUTICAL FOR TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | ALLELIX NEUROSCIENCE INC (US) | 2006-08-02 | — | — | EP | disclosed |
| US-7019024-B2 | Pharmaceutical for treatment of neurological and neuropsychiatric disorders | ALLELIX NEUROSCIENCE INC. (US) | 2006-03-28 | — | — | US | disclosed |
| EP-0812318-B1 | 4-AMINOTETRAHYDROBENZISOXAZOLE OR -ISOTHIAZOLE COMPOUNDS | LUNDBECK & CO AS H (DK) | 2006-02-08 | — | — | EP | disclosed |
| US-20050261372-A1 | Derivatives of glycinergic r(+)-2-amino-3-hydroxypropanoic acid | ORAPHARMA, INC. | 2005-11-24 | — | — | US | disclosed |
| EP-1529030-A2 | DERIVATIVES OF GLYCINERGIC R(+)-2-AMINO-3-HYDROXYPROPANOIC ACID | Prestwick Pharmaceuticals, Inc. (US) | 2005-05-11 | — | — | EP | disclosed |
| WO-2004016580-A2 | DERIVATIVES OF GLYCINERGIC R(+)-2-AMINO-3-HYDROXYPROPANOIC ACID | PRESTWICK PHARMACEUTICALS, INC. (US) | 2004-02-26 | — | — | WO | disclosed |
| EP-1037635-A4 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2002-11-13 | — | — | EP | disclosed |
| US-6476028-B1 | Compounds and methods | SMITHKLINE BEECHAM CORPORATION | 2002-11-05 | — | — | US | disclosed |
| US-5393759-A | Isochromane derivatives | AKZO N.V. (NL) | 1995-02-28 | — | — | US | disclosed |
| US-5334720-A | Diphenyl-1-(aminoalkyl)-2-piperidinone and -2-pyrrolidinone derivatives having anticonvulsant properties | FISONS CORPORATION (US) | 1994-08-02 | — | — | US | disclosed |
| US-5238939-A | Isochromane derivatives | AKZO N.V. (NL) | 1993-08-24 | — | — | US | disclosed |
| EP-0458387-A1 | Isochromane derivatives | Akzo Nobel N.V. (NL) | 1991-11-27 | — | — | EP | disclosed |
| US-4882331-A | ANTIDEPRESSANTS | LES LABORATOIRES MERAM (FR) | 1989-11-21 | — | — | US | disclosed |
| EP-0288360-A1 | Derivatives of 1-[(1,1-diphenyl)-1-alkenyl] piperazine, process for their preparation and compositions containing them | Société anonyme: LES LABORATOIRES MERAM (FR) | 1988-10-26 | — | — | EP | disclosed |
| US-4514414-A | NEUROLEPTIC AGENTS | SMITHKLINE BECKMAN CORPORATION (US) | 1985-04-30 | — | — | US | disclosed |
| EP-0066456-B1 | N-SUBSTITUTED AZAHETEROCYCLIC CARBOXYLIC ACIDS AND THEIR ESTERS | SMITHKLINE BECKMAN CORPORATION (US) | 1985-04-24 | — | — | EP | disclosed |
| US-4383999-A | GAMMA-AMINOBUTYRIC ACID SEDATIVES, ANALGESTICS, ANTIEPILEPTIC, MUSCULAR AND PSYCHOLOGICAL DISORDERS | SMITHKLINE BECKMAN CORPORATION (US) | 1983-05-17 | — | — | US | disclosed |
| EP-0066456-A1 | N-substituted azaheterocyclic carboxylic acids and their esters | SMITHKLINE BECKMAN CORPORATION (US) | 1982-12-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287298-A1 | Pharmaceutical for treatment of neurological and neuropsychiatric disorders | SLC18A2, SLC6A1, SLC6A11 | SIGMAR1 2305/4885TBXAS1 2326/4885CHRNB2 459/4885 |
| US-20050261372-A1 | Derivatives of glycinergic r(+)-2-amino-3-hydroxypropanoic acid | GLRA3, GLRA1, GLRA2 | SIGMAR1 1039/4885TBXAS1 4196/4885CHRNB2 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.